億帆醫藥(002019.SZ):獲得美索巴莫注射液的藥品註冊證書
格隆匯8月6日丨億帆醫藥(002019.SZ)公佈,公司全資子公司合肥億帆生物製藥有限公司於2024年8月5日收到國家藥品監督管理局核准簽發的美索巴莫注射液《藥品註冊證書》。美索巴莫注射液主要用於急性骨骼肌疼痛或不適症狀的治療。
根據IQVIA數據顯示,美索巴莫注射劑2023年全球銷售額為4,043萬美元。根據米內網數據顯示,美索巴莫注射劑2023年國內銷售額3.3億元。
截至報吿披露日,公司對美索巴莫注射液的研發投入約465.37萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.